Investment Rating - The report gives a "Buy" rating for the company with a target price of RMB 37.49, indicating a potential upside of 50% from the current price of RMB 24.95 [2][3][36]. Core Insights - The company is expected to achieve a revenue and profit CAGR of 17.7% and 20.1% respectively from 2023 to 2026, driven by its strong brand influence in the anorectal health sector and effective channel management [6][7]. - The company has successfully reduced inventory levels to the lowest since 2016-2017, which is expected to facilitate a price increase cycle for its hemorrhoid treatment products [7][30]. - The healthcare service segment is seen as a crucial part of the company's strategy to expand its anorectal health ecosystem, although growth may be slow due to industry policies [8][31]. Financial Overview - The company reported a revenue of RMB 3,532 million in 2022, with projections of RMB 3,853 million in 2024 and RMB 4,484 million in 2025, reflecting a positive growth trajectory [9]. - The expected EPS for 2024, 2025, and 2026 are RMB 1.33, RMB 1.59, and RMB 1.78 respectively, indicating a steady increase in profitability [3][9]. - The company’s market capitalization is approximately USD 1.485 billion, with a current share count of 431 million [3]. Business Segments - The company's pharmaceutical segment, particularly hemorrhoid treatments, accounts for over 70% of its pharmaceutical revenue, highlighting its market leadership [7][29]. - The health products segment, which includes eye care and skincare, is projected to grow at a CAGR of 34.8% from 2023 to 2026, driven by product innovation [7][30]. - The medical services segment, while facing growth challenges, is expected to expand gradually as the company continues to develop its diagnostic and treatment centers [8][31]. Market Position - The company has established itself as a leading brand in the hemorrhoid treatment market, with a significant market share and a reputation for high-quality products [7][55]. - The hemorrhoid treatment market in China is projected to grow from RMB 49.73 billion in 2022 to RMB 74.75 billion by 2028, with a CAGR of 7.0% from 2023 to 2028 [44]. - The company’s pricing strategy has positioned it favorably against competitors, allowing for potential price increases in the future [64][70].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$30.40, representing a potential upside of 31% from the current price of HK$23.20 [1][8][9] Core Insights - The company has shown a recovery path, with a 10% quarter-on-quarter revenue growth in Q3 2024, although the price increase was less than expected [1][4] - The gross margin for Q3 2024 exceeded expectations at 12.2%, compared to the forecast of 11.5% [1][4] - The management indicated strong growth in consumer electronics, but weakness persists in industrial and automotive sectors [1][4] - Revenue forecasts for 2025 have been adjusted downwards to a 23% year-on-year growth, a reduction of 5% from previous estimates [1][5] Financial Summary - The company reported a net profit of US$45 million in Q3 2024, which was 9% higher than the forecast [4] - The projected earnings per share (EPS) for 2024 is US$0.08, with subsequent years expected to rise to US$0.12 in 2025 and US$0.16 in 2026 [1][5] - Revenue for 2024 is forecasted at US$2,003 million, with a projected increase to US$2,461 million in 2025 and US$2,953 million in 2026 [5][14] Valuation - The valuation approach is based on a price-to-book (P/B) ratio, with a target P/B of 1.0 times and an estimated book value per share of US$3.87 for 2025 [8][9] - The report highlights that the company’s long-term return on equity (ROE) prospects remain challenging due to high capital expenditures and competitive pressures in traditional processes [8][9] Market Comparison - The company’s current market capitalization is approximately US$5.13 billion, with a P/E ratio of 38.7 for the next fiscal year [9] - Compared to peers, the company has a lower P/B ratio of 0.8, indicating potential undervaluation relative to its competitors [9]

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 520.00, representing a potential upside of approximately 28.8% from the current price of HKD 403.80 [2][17]. Core Insights - The report highlights strong growth in the gaming sector, particularly in domestic games, driven by titles such as "Dungeon & Fighter Mobile" and other flagship games, with a projected 4Q24 year-on-year growth of 16% for both domestic and international games [2][14]. - The advertising segment continues to show robust growth, with a year-on-year increase of 17%, supported by WeChat features [2][10]. - The report notes a significant increase in net profit, with a year-on-year growth of 33% in 3Q24, surpassing previous forecasts [2][10]. Financial Performance Summary - The total net revenue for 3Q24 was RMB 167.19 billion, reflecting an 8% year-on-year increase [10]. - The gaming revenue for 3Q24 reached RMB 51.80 billion, with a 13% year-on-year growth, and domestic games grew by 14% [10]. - The report projects a total revenue of RMB 658.95 billion for 2024, with a slight adjustment reflecting a 0% change from previous estimates [15]. Revenue Breakdown - Domestic mobile game revenue is expected to reach RMB 131.79 billion in 2024, showing a 9.5% year-on-year increase [8]. - The report indicates that the advertising segment's gross margin has slightly decreased, while the overall revenue structure is shifting towards higher-margin businesses [14][15]. - The financial technology and enterprise services segment is projected to grow by 2% year-on-year in 4Q24, indicating a stable performance despite market challenges [10][14]. Earnings Per Share (EPS) Forecast - The report updates the EPS forecast for 2024 to RMB 22.82, reflecting a 1% increase from previous estimates [2][15]. - For 2025, the EPS is projected to be RMB 25.46, a 3% increase from earlier forecasts [2][15]. - The 2026 EPS forecast is set at RMB 28.32, also reflecting a 3% increase [2][15].

Industry Investment Rating - Overweight rating for the automotive and auto parts industry [2] Core Views - October passenger vehicle wholesale sales hit a record high, with new energy vehicle (NEV) penetration rate stabilizing above 50% [2] - Retail and wholesale sales of passenger vehicles in October achieved double-digit year-on-year growth, with NEV sales increasing by 55.9% YoY and 6.5% MoM [2] - The cumulative penetration rate of NEVs in the first 10 months reached 46.5% [2] - Power battery sales and installations in October increased by 6.2% and 8.6% MoM, respectively, with lithium iron phosphate (LFP) batteries accounting for nearly 80% [2] - Both high-end and low-end market segments showed strong growth, and production and wholesale volumes are expected to continue growing in November during the restocking period [2] Market Performance - In October, retail sales of passenger vehicles reached 2.28 million units, up 12.1% YoY and 7.3% MoM, while wholesale sales reached 2.668 million units, up 12.6% YoY and 9.3% MoM [3] - NEV retail sales in October were 1.196 million units, up 55.9% YoY and 6.5% MoM, with a penetration rate of 52.5% [3] - Cumulative NEV retail and wholesale sales from January to October were 8.331 million and 9.208 million units, respectively, up 32.5% and 39.8% YoY [3] - Passenger vehicle exports in October were 441,000 units, up 13.0% YoY and 2.0% MoM, with cumulative exports in the first 10 months reaching 3.991 million units, up 30.0% YoY [3] - NEV exports in October were 120,000 units, up 10.4% YoY and 13.7% MoM, with cumulative exports in the first 10 months reaching 1.088 million units, up 27.7% YoY [3] Battery Market - In October, power and energy storage battery sales totaled 110.3 GWh, up 47.4% YoY and 6.2% MoM, with power battery sales accounting for 79.1 GWh, up 30.6% YoY and 3.3% MoM [4] - Cumulative power and energy storage battery sales from January to October were 796.0 GWh, up 43.2% YoY [4] - Power battery installations in October were 59.2 GWh, up 51.0% YoY and 8.6% MoM, with LFP batteries accounting for 79.4% of total installations [4] - Ternary battery installations in October were 12.2 GWh, down 1.1% YoY and 7.2% MoM, accounting for 20.6% of total installations [4] Market Segments - High-end and low-end market segments showed strong growth in October, driven by national scrappage and local replacement subsidy policies [5] - As of November 6, over 1.7 million applications for vehicle scrappage subsidies were submitted nationwide, indicating rapid growth in replacement demand [5] - November is traditionally a period of strong restocking, with manufacturers expected to increase production to meet year-end demand [5] Top NEV Models - The top 5 NEV models by sales in October were: BYD Seagull (51,288 units), BYD Qin L DM-i (39,316 units), BYD Seal 06 (38,069 units), Tesla Model Y (36,204 units), and Wuling Hongguang MINI EV (34,185 units) [7] Battery Installations by Companies - In October, CATL led with 25.32 GWh of battery installations, accounting for 42.78% of the market, followed by BYD with 15.82 GWh (24.73%) [11] - Cumulative installations from January to October were 183.02 GWh for CATL and 100.67 GWh for BYD [11] Policy Updates - Key policies in October included Shanghai's financial support for hydrogen storage and fuel cell vehicle projects, and the Ministry of Industry and Information Technology's announcement of new pilot cities for full electrification of public vehicles [16] - Other policies focused on promoting renewable energy and improving charging infrastructure [16] Company News - XPeng held its AI DAY on November 6, showcasing new technologies and launching the P7+ model with a starting price of 186,800 RMB [17] - Leapmotor announced that it expects to achieve profitability earlier than previously anticipated [17] - Huawei's HarmonyOS Smart Selection launched the new S7 model with a pre-sale price starting at 248,000 RMB [17] - BYD collaborated with Huawei to launch the Bao 8 smart off-road vehicle, priced between 379,800 RMB and 407,800 RMB [17] - Tesla CEO Elon Musk was announced as a co-leader of a proposed government efficiency department under the Trump administration [17] - Seres announced a cash dividend of 0.331 RMB per share, totaling 500 million RMB [17]

Investment Rating - Buy rating maintained with a target price of $122.25, representing an 18% increase from the previous target price [1][4] - The target price implies a 25x 2025 P/E and a 17% upside from the current price [4][6] Core Views - Expansion logic remains sound with strong fundamentals, driven by successful entry into new product categories such as outdoor fans, portable coolers, and cold beverage machines [2] - Short-term catalysts are lacking, and the stock may continue to fluctuate within the $90-$110 range over the next 2-3 months [3] - Revenue and adjusted net profit for 2024 are expected to grow by 27.5% and 35.2% YoY, respectively [2][4] Financial Performance and Forecasts - 2024E revenue is projected at $5.423 billion, up 27.5% YoY, with adjusted net profit of $607 million, up 35.2% YoY [4][5] - 2025E revenue is forecasted at $6.100 billion, a 12.5% YoY increase, with adjusted net profit of $686 million, up 12.9% YoY [4][5] - 2026E revenue is expected to reach $6.830 billion, growing 12.0% YoY, with adjusted net profit of $783 million, up 14.2% YoY [4][5] Product and Market Expansion - Successful product launches, including the CREAMi ice cream maker, which now contributes high single-digit revenue share after initial slow growth [2] - Plans to expand SKUs for outdoor fans and portable coolers, with further growth expected in Europe [2] - New product categories such as semi-automatic coffee machines and multi-functional beauty devices are expected to drive future growth [2] Valuation and Peer Comparison - Current 2025E P/E of 21.3x, compared to the peer average of 13.8x [8] - SharkNinja's valuation is higher than peers like Whirlpool (9.8x 2025E P/E) and Reynolds Consumer (15.7x 2025E P/E) [8] Financial Ratios and Metrics - 2024E gross margin is expected to improve to 48.2%, up from 44.9% in 2023A [9] - 2024E adjusted net margin is forecasted at 11.2%, with ROE of 22.7% [9] - Free cash flow is projected to grow from $868 million in 2024E to $1.149 billion in 2026E [9]

Investment Rating - The report assigns an "Overweight" rating to the healthcare industry [1]. Core Viewpoints - The establishment of the medical insurance prepayment system is expected to enhance operational efficiency in the healthcare sector [1][2]. - The prepayment system will alleviate the financial pressure on medical institutions, thereby improving their operational efficiency and promoting stable operations for pharmaceutical and consumable companies [1][2]. - The report expresses optimism about the development prospects of the healthcare service industry, recommending companies such as Haijia (603939CH, Buy rating, target price RMB 47.90), Gushengtang (2273 HK, Buy rating, target price HK$ 73.95), and Jinxin Reproductive (1951 HK, Buy rating, target price HK$ 4.78) [3]. Summary by Sections Medical Insurance Prepayment System - The prepayment system aims to help medical institutions manage cash flow pressures and enhance service capabilities, specifically for drug and consumable expenditures [2]. - The prepayment amount will be based on the average monthly expenditure of the medical insurance fund over the previous 1-3 years, adjusted according to the annual comprehensive evaluation and credit rating of the medical institutions [2]. Industry Outlook - The report anticipates that the implementation of the prepayment system will accelerate cash flow in the Chinese healthcare service industry, leading to improved operational efficiency [3].

Industry Investment Rating - Overweight rating for the pharmaceutical retail industry [1] Core Views - The pharmaceutical retail business has shown strong revenue growth resilience in the first 8 months of 2024 [1] - The pharmaceutical retail industry is expected to achieve improved profit margins in the future, with Yifeng Pharmacy being the top recommendation [1][2] - The industry is transitioning from store expansion to profitability enhancement, maintaining long-term growth potential [2] Revenue Growth and Channel Analysis - From January to August 2024, the pharmaceutical retail market in China reached a sales scale of RMB 3,244 billion, with a year-on-year growth rate of 1.4% [1] - Retail pharmacies (including O2O) accounted for 87.0% of the market, with a year-on-year growth rate of 0.3% [1] - E-commerce B2C accounted for 13.0% of the market, with a year-on-year growth rate of 9.6%, and its market share increased by 1.0% compared to the previous year [1] - In July and August 2024, offline retail pharmacy revenue grew by 2% and 5% year-on-year, respectively, indicating a clear improvement in the performance of physical pharmacies [2] Channel Differentiation and Product Focus - Retail pharmacies, due to their professional nature, focus on categories such as oncology drugs, cardiovascular drugs, and hypertension medications [2] - Online platforms, leveraging privacy, prioritize categories like dermatological drugs and urological medications [2] - O2O, as an emerging field, is increasingly important for retail growth, particularly for acute medication needs such as cold medicines, cough suppressants, and systemic anti-infective drugs [2] Company Recommendation - Yifeng Pharmacy (603939CH) is recommended with a "Buy" rating and a target price of RMB 47.90 [2]

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------------|-------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------|------------------------------------------|------------------|--- ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of US$28.90, representing a potential upside of 15% from the current price of US$25.06 [1][4][12]. Core Insights - The company is expected to deliver between 160,000 to 170,000 new vehicles in Q4 2024, with projected revenue ranging from RMB 432 billion to RMB 459 billion, indicating a year-on-year growth of 3.5% to 10% [4][6]. - The gross margin for Q3 2024 improved significantly, reaching 21.5%, driven by a decrease in vehicle costs, despite some offset from the increased delivery of lower-priced models [5][10]. - The report highlights a substantial increase in operating profit for Q3 2024, which reached RMB 34.3 billion, a remarkable growth of 633.4% quarter-on-quarter [5][10]. Financial Performance Summary - The company reported Q3 2024 revenue of RMB 428.7 billion, a year-on-year increase of 23.6% and a quarter-on-quarter increase of 35.3% [5][9]. - The projected earnings per share (EPS) for 2024 is RMB 11.12, reflecting a 38% increase from previous estimates [1][11]. - The forecasted revenue for 2024 is RMB 145,464 million, with a gross profit of RMB 30,503 million, indicating a gross margin of 21.0% [8][11]. Adjustments and Forecasts - The report adjusts the company's 2024-2026 gross margin estimates upward to reflect the ongoing decrease in unit costs, with the gross margin expected to range from 21.0% to 23.2% [7][10]. - Non-GAAP net profit estimates for 2024, 2025, and 2026 have been revised to RMB 108.9 billion, RMB 147.0 billion, and RMB 191.2 billion respectively, showing a growth trajectory [10][11]. - The company is expected to maintain a steady monthly sales volume exceeding 50,000 units, supported by the upcoming BEV new vehicle cycle in 2025 [12][10].

Investment Rating - The report maintains a "Buy" rating for China Merchants Bank-H (3968 HK) with a target price of HK$48.90, representing a potential upside of 29% from the current price of HK$38.00 [1][5]. Core Views - The bank's 3Q24 earnings met expectations, benefiting from effective cost control that offset declines in interest and commission income. The adjusted net profit for 3Q24 was RMB 38.4 billion, a year-on-year increase of 0.8% [6][10]. - Revenue growth continues to slow, with a year-on-year decline of 2.6%, primarily due to a 14 basis point decrease in net interest margin, which offset a 4.7% increase in loans [6][12]. - The bank's asset quality showed relative improvement, with a non-performing loan ratio stable at 0.94% and a high coverage ratio of 432.2% [7][14]. - The outlook for 4Q24 and 2025 suggests a continued decline in net interest margin, although the pace of decline is expected to slow. Credit demand is anticipated to recover in 2025 [8][12]. Summary by Sections Earnings Performance - In 3Q24, adjusted net profit was RMB 38.4 billion, with a year-to-date adjusted net profit of RMB 111.2 billion, flat year-on-year [6][10]. - The bank's total revenue for 3Q24 was RMB 79.1 billion, down 2.6% year-on-year, driven by a decrease in net interest income and commission income [13]. Financial Metrics - The bank's cost-to-income ratio improved to 32.6%, down from 34.3% in 2Q24, indicating better cost management [7][14]. - The core Tier 1 capital ratio increased by 87 basis points to 14.73%, reflecting strengthened capital levels [7][14]. Future Outlook - The bank expects a decline in net interest margin in 4Q24, but the decrease is projected to be less severe than in 2024. Loan growth is expected to exceed 2024 levels, particularly in retail loans [8][12]. - The bank's ability to generate positive growth in commission income in 2025 will depend on regulatory decisions regarding fee reductions [8][12].